GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...